AnaMar Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 8

Employees

  • Latest Deal Type
  • 2ndary - Private

AnaMar General Information

Description

Developer of novel therapeutic drugs intended to prevent, heal, and slow organ scarring due to fibrotic disease. The company's drugs target the extracellular matrix producing myofibroblast to treat systemic sclerosis, enabling physicians to treat skin and lung manifestations of systemic sclerosis with a favorable safety profile.

Contact Information

Website
www.anamar.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Birger Jarlsgatan 57
  • Floor 7
  • 113 56 Stockholm
  • Sweden
+46 031-732
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • Birger Jarlsgatan 57
  • Floor 7
  • 113 56 Stockholm
  • Sweden
+46 031-732

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AnaMar Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private Completed Pre-Clinical Trials
4. Secondary Transaction - Private 03-Jun-2013 Completed Pre-Clinical Trials
3. Later Stage VC 07-Nov-2008 Completed Pre-Clinical Trials
2. Early Stage VC 01-Jan-2002 Completed Startup
1. Merger/Acquisition 01-Jan-1998 Completed Startup
To view AnaMar’s complete valuation and funding history, request access »

AnaMar Patents

AnaMar Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024245894-A1 (4r)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro-1h-pyrazole-1-carboximidamide hydrochloride and dermal formulations thereof Inactive 26-May-2023
WO-2024245895-A1 Enantioselective preparation method Inactive 26-May-2023
AU-2020295685-A1 New tricyclic 5-ht2 antagonists Inactive 18-Jun-2019
CA-3141747-A1 New tricyclic 5-ht2 antagonists Pending 18-Jun-2019
EP-3753924-A1 New tricyclic 5-ht2 antagonists Inactive 18-Jun-2019 C07D209/60
To view AnaMar’s complete patent history, request access »

AnaMar Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AnaMar Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alestra Growth/Expansion Minority
Allegro Investment Fund Venture Capital Minority
Allenex Corporation Minority
Koncentra PE-Backed Company Minority
To view AnaMar’s complete investors history, request access »

AnaMar FAQs

  • When was AnaMar founded?

    AnaMar was founded in 1998.

  • Where is AnaMar headquartered?

    AnaMar is headquartered in Stockholm, Sweden.

  • What is the size of AnaMar?

    AnaMar has 8 total employees.

  • What industry is AnaMar in?

    AnaMar’s primary industry is Drug Discovery.

  • Is AnaMar a private or public company?

    AnaMar is a Private company.

  • What is AnaMar’s current revenue?

    The current revenue for AnaMar is .

  • How much funding has AnaMar raised over time?

    AnaMar has raised $9.9M.

  • Who are AnaMar’s investors?

    Alestra, Allegro Investment Fund, Allenex, and Koncentra have invested in AnaMar.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process